Latest Legal News

Page 10 of 216
Identitii’s BNDRY platform gained customers and recurring revenue in FY26, but the company ended the year with just $107,483 in cash, negative net assets and a material uncertainty over its ability to continue as a going concern. A subsequent convertible note facility provides a committed $5 million, while access to a further $15 million remains conditional.
Victor Sage
Victor Sage
30 Sept 2026
GWR Group has swung to a $26.84 million FY2026 loss after impairing Gold Valley receivables and booking a $10.19 million rehabilitation provision linked to Wiluna West. The company still holds $37.13 million in cash, but its accounts warn of material uncertainty after a $19.85 million capital distribution to shareholders.
Maxwell Dee
Maxwell Dee
29 Sept 2026
Cauldron Energy has expanded its defined Yanrey uranium resource to 55.6 million pounds of U3O8 after a successful exploration year, while warning that further funding will be needed to continue operations. The project remains dependent on a change to Western Australia’s uranium mining policy.
Maxwell Dee
Maxwell Dee
29 Sept 2026
Beacon Minerals has reported a sharp FY2026 recovery, underpinned by higher gold revenue, Lady Ida production and a substantial increase in the Iguana Ore Reserve. The headline profit includes a sizeable asset-sale gain, leaving the next test focused on recurring mine performance.
Maxwell Dee
Maxwell Dee
29 Sept 2026
Blaze Minerals reported a narrower FY2026 loss, but ended the year with just $43,552 in cash and an auditor-highlighted material uncertainty over its ability to continue as a going concern. The company is relying on shareholder-approved funding, a proposed 20:1 consolidation and a conditional Ugandan tungsten acquisition to reshape its next phase.
Maxwell Dee
Maxwell Dee
29 Sept 2026
Riedel Resources has completed the equity-funded acquisition of the Cosmo and Mt Venn gold projects, expanding its exploration portfolio beyond Arizona. But the annual report carries a material going-concern uncertainty, leaving future drilling dependent on further capital and execution.
Maxwell Dee
Maxwell Dee
29 Sept 2026
Eclipse Metals has enlarged its flagship Grønnedal rare-earth resource to 208 million tonnes and added a maiden Ivigtût critical-minerals inventory. The gains came alongside a higher annual loss, a material going-concern uncertainty and an unresolved legal claim.
Maxwell Dee
Maxwell Dee
29 Sept 2026
Melbana Energy’s Block 9 project remains on care and maintenance after a partner default and US sanctions on CUPET, despite improved geological understanding from Amistad-2. The company ended FY2026 with $472,504 in cash and warned that additional funding is required to continue.
Victor Sage
Victor Sage
29 Sept 2026
Neuren says its partner Acadia has received a US Notice of Allowance for a trofinetide patent that could protect weight-banded dosing through 28 March 2041. The patent has not yet formally issued, but the allowance could extend US protection by almost five years beyond the existing method-of-use patent.
Ada Torres
Ada Torres
29 Sept 2026
The Takeovers Panel has allowed Pengana Capital Group to withdraw its challenge to Pengana International Equities’ buy-back and proposed rights issue, but stopped short of endorsing the transactions. The regulator said it remained concerned about the structure and warned that settlement terms must not obstruct future proceedings.
Claire Turing
Claire Turing
29 Sept 2026
Anson Resources has secured approval for 17 additional Utah lease blocks covering 16.02 square kilometres inside the Green River Lithium Project’s resource area of interest. The company says the expanded ground could support a larger JORC resource without further drilling, but the proposed exploration target remains conceptual and the lease is not yet signed.
Maxwell Dee
Maxwell Dee
29 Sept 2026
Argent BioPharma has secured exclusive commercialisation rights to selected Tollovir, Tollovid and NutraVir antiviral products in a worldwide deal excluding China. The agreement adds a new commercial pillar alongside CimetrA®, but does not itself grant pharmaceutical development rights or establish clinical efficacy.
Victor Sage
Victor Sage
29 Sept 2026

Browse the archive

Full archive